China's National Healthcare Security Administration Completes 2026 Drug Catalog Adjustment Applications
Quick Look
- China's National Healthcare Security Administration announced the closure of applications for the 2026 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog and Commercial Health Insurance Innovative Drug Catalog adjustments on June 10.
- A total of 818 drug applications were received, an increase from the previous year.
AI-generated summary
Why It Matters
China's National Healthcare Security Administration is undertaking the annual adjustment of its drug catalogs, which include basic medical insurance and commercial health insurance. The application period for the 2026 catalog adjustments has concluded.
中新网6月11日电 据“国家医保局”微信公众号消息，按照《2026年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案》，2026年基本医保目录及商保创新药目录调整申报已于6月10日20:00结束。
申报期间共收到818份药品申报材料，包括目录外药品570份(单独申报基本目录509份，单独申报商保创新药目录17份，同时申报基本目录和商保目录44份)，目录内药品248份，总体数量较2025年进一步增加。
下一步国家医保局将对收到的申报材料逐一进行形式审查，并就初审结果向社会公示。
What to Watch
AI outlook — possibilities, not facts
The National Healthcare Security Administration will conduct a formal review of the submitted drug applications.
Very likely · Within weeks
The preliminary review results will be made public.
Very likely · Within weeks
Open Questions
- What are the criteria for reviewing the submitted drug applications?
- When will the preliminary review results be announced?
- What is the timeline for the finalization of the 2026 drug catalogs?
